ArticleChemical communications (Cambridge, England)2017
X-ray crystallographic structure of a teixobactin analogue reveals key interactions of the teixobactin pharmacophore.
Article in Chemical communications (Cambridge, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Understanding the Role of Macrocycle Size and Amide Linkage in Teixobactin Analogues.Biomolecules · 2026Article
- Drug repurposing of natural depsipeptide fromFrontiers in pharmacology · 2025Article
- Structure-Activity Relationship Studies of the Peptide Antibiotic Clovibactin.The Journal of organic chemistry · 2024Article
- Supramolecular Interactions of Teixobactin Analogues in the Crystal State.The Journal of organic chemistry · 2024Article
- New Teixobactin Analogues with a Total Lactam Ring.ACS medicinal chemistry letters · 2023Article
- Synthesis and Stereochemical Determination of the Peptide Antibiotic Novo29.The Journal of organic chemistry · 2023Article
- Isobactins:Chemical science · 2022Article
- Computer-Aided Drug Design Boosts RAS Inhibitor Discovery.Molecules (Basel, Switzerland) · 2022Review
- Linearized teixobactin is inactive and after sequence enhancement, kills methicillin-resistant Staphylococcus aureus via a different mechanism.Peptide science (Hoboken, N.J.) · 2022Article
- Article
- Molecular Dynamics Insight into the Lipid II Recognition by Type A Lantibiotics: Nisin, Epidermin, and Gallidermin.Micromachines · 2021Article
- Emerging peptide antibiotics with therapeutic potential.Medicine in drug discovery · 2021Review
- A Review on Applications of Computational Methods in Drug Screening and Design.Molecules (Basel, Switzerland) · 2020Review
- Design, Synthesis, and Study of Lactam and Ring-Expanded Analogues of Teixobactin.The Journal of organic chemistry · 2020Article
- Thiol-ene Enabled Chemical Synthesis of TruncatedFrontiers in chemistry · 2020Article
- Structural studies suggest aggregation as one of the modes of action for teixobactin.Chemical science · 2018Article
- X-ray Crystallographic Structure of a Teixobactin Derivative Reveals Amyloid-like Assembly.Journal of the American Chemical Society · 2018Article
- Cysteines and Disulfide-Bridged Macrocyclic Mimics of Teixobactin Analogues and Their Antibacterial Activity Evaluation against Methicillin-ResistantPharmaceutics · 2018Article
- Probing key elements of teixobactin-lipid II interactions in membranes.Chemical science · 2018Article
- In silico approach in reveal traditional medicine plants pharmacological material basis.Chinese medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The X-ray crystallographic structure of a truncated teixobactin analogue reveals hydrogen-bonding and hydrophobic interactions and a cavity that binds a chloride anion. Minimum inhibitory concentration (MIC) assays against Gram-positive bacteria correlate the observed structure with antibiotic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.